Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Payables (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Payables for 15 consecutive years, with $76000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Payables fell 80.81% to $76000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $76000.0, a 80.81% decrease, with the full-year FY2024 number at $609000.0, down 32.78% from a year prior.
  • Payables was $76000.0 for Q3 2025 at NovaBay Pharmaceuticals, down from $604000.0 in the prior quarter.
  • In the past five years, Payables ranged from a high of $1.6 million in Q1 2022 to a low of $76000.0 in Q3 2025.
  • A 5-year average of $916947.4 and a median of $947000.0 in 2023 define the central range for Payables.
  • Peak YoY movement for Payables: plummeted 85.09% in 2021, then surged 347.12% in 2022.
  • NovaBay Pharmaceuticals' Payables stood at $1.0 million in 2021, then grew by 3.35% to $1.1 million in 2022, then decreased by 16.11% to $906000.0 in 2023, then tumbled by 32.78% to $609000.0 in 2024, then tumbled by 87.52% to $76000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Payables are $76000.0 (Q3 2025), $604000.0 (Q2 2025), and $800000.0 (Q1 2025).